Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
RATIONALE: Halofuginone hydrobromide may stop the growth of solid tumors by stopping blood flow to the tumor.
PURPOSE: Phase I trial to study the effectiveness of halofuginone hydrobromide in treating patients who have progressive advanced solid tumors.
|Unspecified Adult Solid Tumor, Protocol Specific||Drug: halofuginone hydrobromide||Phase 1|
|Study Design:||Primary Purpose: Treatment|
|Official Title:||Phase I Study To Determine The Safety Of Halofuginone In Patients With A Solid Progressive Tumor|
|Study Start Date:||August 2001|
|Primary Completion Date:||February 2004 (Final data collection date for primary outcome measure)|
- Determine the toxicity profile, maximum tolerated dose, and dose-limiting toxic effects of halofuginone hydrobromide in patients with progressive advanced solid tumors.
- Establish a recommended dose of this drug for phase II study.
OUTLINE: This is a dose-escalation, multicenter study.
Patients receive oral halofuginone hydrobromide once daily on days 1 and 4-14 of course 1 and on days 1-14 of subsequent courses. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 1-3 patients receive escalating doses of halofuginone hydrobromide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 20% of patients experience acute dose-limiting toxicity. After the MTD is reached, 6-12 additional patients are treated at dose levels preceding the MTD until the recommended dose for phase II study is determined. The recommended dose for phase II study is defined as the dose preceding the MTD that allows a 90% dose intensity for 2 months with no greater than grade 2 toxicity in 80% of the patients.
Patients are followed every 8 weeks until disease progression or initiation of another treatment.
PROJECTED ACCRUAL: Approximately 7-40 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00027677
|Leuven, Belgium, B-3000|
|University Hospital - Rotterdam Dijkzigt|
|Rotterdam, Netherlands, 3000 CA|
|Daniel Den Hoed Cancer Center at Erasmus Medical Center|
|Rotterdam, Netherlands, 3008 AE|
|Study Chair:||Maja De Jonge, MD, PhD||Daniel Den Hoed Cancer Center at Erasmus Medical Center|